Sonoma Pharmaceuticals, Inc. SNOA
Inc. in 1999 under the laws of the State of California. We changed our name to Oculus Innovative Sciences, Inc. in 2001. In December 2006
we reincorporated under the laws of the State of Delaware, and in December 2016 we changed our name to Sonoma Pharmaceuticals, Inc.
Conestoga Court, Suite 150, Boulder, Colorado 80301. We have two active wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A.
de C.V., and Sonoma Pharmaceuticals Netherlands, B.V. Our fiscal year end is March 31. Our corporate telephone number is (800) 759-9305.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by segment
- Human Care - Product
- Animal Care - Product
| Segment | FY2025 | FY2024 |
|---|---|---|
| Human Care - Product | $17.7M | $12.6M |
| Animal Care - Product | $1.8M | $1.7M |
As the company reported it, from the “Revenue Disaggregation (Details - Disaggregation of revenue by source)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $14.3M | $12.7M | $13.3M | $12.6M | $18.6M | $17.9M | $19.0M | $16.7M | $12.8M |
| Cost of revenue | $12.1M | $8.8M | $8.0M | $8.8M | $8.6M | $12.1M | $9.8M | $10.1M | $9.3M | $7.2M |
| Gross profit | $7.4M | $5.5M | $4.7M | $4.5M | $4.0M | $6.6M | $8.1M | $8.9M | $7.3M | $5.7M |
| R&D | $2.3M | $1.8M | $1.9M | $207.0K | $125.0K | $555.0K | $1.3M | $1.5M | $1.6M | $1.6M |
| SG&A | $7.6M | $7.4M | $7.6M | $8.8M | $9.8M | $9.5M | $14.2M | $18.6M | $19.9M | $17.1M |
| Total operating expenses | $9.9M | $9.2M | $9.4M | $9.0M | $9.9M | $10.0M | $15.5M | $20.1M | $21.5M | $18.6M |
| Operating income | -$2.5M | -$3.7M | -$4.7M | -$4.6M | -$5.9M | -$3.4M | -$7.4M | -$11.3M | -$14.2M | -$13.0M |
| Interest expense | — | — | — | $16.0K | $10.0K | $4.0K | $16.0K | $33.0K | $40.0K | $3.0K |
| Pre-tax income | -$3.4M | -$2.9M | -$5.0M | -$5.2M | -$5.4M | -$3.9M | -$3.5M | -$11.3M | -$14.3M | -$12.9M |
| Income tax | $244.0K | $550.0K | $196.0K | $33.0K | $332.0K | $713.0K | $29.0K | $458.0K | $50.0K | $4.3M |
| Net income | $3.2K | $3.5K | $4.8K | -$5.2M | -$5.1M | -$4.0M | -$3.3M | -$11.8M | -$14.3M | $9.3M |
| EPS, basic | -1.89 | -2.79 | -10.63 | -1.52 | -1.92 | — | — | — | — | — |
| EPS, diluted | -1.89 | -2.79 | -10.63 | -1.52 | -1.92 | -1.97 | -2.24 | -12.77 | -28.49 | 2.20 |
| Shares, diluted (wtd. avg.) | 1.7M | 1.2M | 455,000 | 3.4M | 2,653 | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.4M | $5.4M | $3.1M | $3.8M | $7.4M | $4.2M | $3.7M | $3.7M | $10.1M | $17.5M |
| Receivables | $2.5M | $2.2M | $2.9M | $2.6M | $2.4M | $2.8M | $4.0M | $3.5M | $1.5M | $2.1M |
| Inventory | $3.7M | $2.9M | $2.7M | $2.9M | $2.7M | $2.5M | $2.2M | $3.4M | $2.9M | $2.2M |
| Total current assets | $12.1M | $12.6M | $12.5M | $13.8M | $16.4M | $13.0M | $12.3M | $12.5M | $16.3M | $22.6M |
| Property, plant and equipment | $310.0K | $225.0K | $365.0K | $488.0K | $320.0K | $360.0K | $365.0K | $727.0K | $1.1M | $1.2M |
| Total assets | $14.0M | $13.7M | $14.7M | $16.2M | $18.8M | $15.0M | $14.6M | $14.4M | $19.2M | $25.5M |
| Accounts payable | $1.9M | $953.0K | $607.0K | $841.0K | $1.6M | $1.8M | $2.1M | $1.3M | $1.3M | $1.3M |
| Short-term debt | $222.0K | $220.0K | $323.0K | $431.0K | — | $596.0K | $481.0K | $322.0K | $230.0K | $123.0K |
| Total current liabilities | $4.8M | $4.1M | $3.7M | $3.7M | $5.8M | $4.1M | $4.7M | $3.6M | $3.3M | $3.3M |
| Long-term debt | — | — | — | — | $0 | $1.3M | $0 | $12.0K | $32.0K | $45.0K |
| Total liabilities | $10.9M | $9.3M | $8.6M | $8.3M | $10.1M | $9.6M | $8.9M | $4.0M | $3.9M | $4.0M |
| Retained earnings | -$201.0M | -$197.8M | -$194.3M | -$189.5M | -$184.4M | -$179.3M | -$175.3M | -$169.2M | -$157.4M | -$143.1M |
| Total equity | $3.1M | $4.4M | $6.1M | $8.0M | $8.7M | $5.4M | $5.6M | $7.8M | $15.3M | $21.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.9M | -$88.0K | -$2.4M | -$6.2M | -$4.2M | -$3.4M | -$4.6M | -$11.7M | -$12.4M | -$8.2M |
| Depreciation and amortisation | $139.0K | $138.0K | $176.0K | $125.0K | $186.0K | $227.0K | $312.0K | $453.0K | $490.0K | $248.0K |
| Stock-based compensation | $255.0K | $224.0K | $516.0K | $669.0K | $382.0K | $371.0K | $839.0K | $1.6M | $2.5M | $2.1M |
| Capital expenditure | $192.0K | $80.0K | $2.0K | $269.0K | $137.0K | $179.0K | $206.0K | $100.0K | $187.0K | $394.0K |
| Investing cash flow | -$192.0K | -$80.0K | -$2.0K | -$258.0K | -$99.0K | $388.0K | $3.6M | -$131.0K | -$201.0K | $18.2M |
| Financing cash flow | $477.0K | $3.0M | $1.7M | $2.5M | $7.4M | $3.3M | $1.0M | $5.5M | $5.2M | -$32.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001683168-26-005810.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.8M | $16.7M | $19.0M | $17.9M | $18.6M | $12.6M | $13.3M | $12.7M | $14.3M | $19.5M |
| Gross profit | $5.7M | $7.3M | $8.9M | $8.1M | $6.6M | $4.0M | $4.5M | $4.7M | $5.5M | $7.4M |
| Net income | $9.3M | -$14.3M | -$11.8M | -$3.3M | -$4.0M | -$5.1M | -$5.2M | $4.8K | $3.5K | $3.2K |
Recent filings and events
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event Item 8.01
- Material agreement signed Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event Item 8.01
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |